Home > Insider Trading > Filing (0001104659-13-080067)

Filing Details

Accession Number:: 0001104659-13-080067
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2013-11-01 16:13:08
Reporting Period:: 2013-10-31

Filing Date:: 2013-11-01
Accepted Time:: 2013-11-01 16:13:08
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1104506	Insmed Inc	INSM	Pharmaceutical Preparations (2834)	541972729

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1402051	William Lewis	C/O Insmed Inc 9 Deer Park Drive, Suite C Monmouth Junction NJ 08852	President And Ceo	Yes	Yes	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2013-11-01	5,233	$14.28	46,972	No	4	P	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	P	Direct

Reported Derivative Holdings

Show Other Fields >>

Sec. Name	Sec. Type	Price	Date	Expiration Date	Amount	Remaning Holdings	Nature of Ownership
Common Stock	Stock Option-Right to Buy	$3.40	2013-09-10	2022-09-10	708,314	708,314	Direct
Common Stock	Stock Option-Right to Buy	$4.55	2013-09-28	2022-09-28	186,170	186,170	Direct
Common Stock	Stock Option-Right to Buy	$12.44	2014-05-23	2023-05-23	83,333	83,333	Direct
Common Stock	Stock Option-Right to Buy	$12.44		2023-05-23	166,667	166,667	Direct
Common Stock	Stock Option-Right to Buy	$14.24	2014-10-31	2013-10-31	250,000	250,000	Direct

Expiration Date	Amount	Remaning Holdings	Nature of Ownership
2022-09-10	708,314	708,314	Direct
2022-09-28	186,170	186,170	Direct
2023-05-23	83,333	83,333	Direct
2023-05-23	166,667	166,667	Direct
2013-10-31	250,000	250,000	Direct

Footnotes

Open market purchase pursuant to a 10b5-1 trading plan adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.15 to $14.46, inclusive. The reporting person undertakes to provide to Insmed Incorporated, any security holder of Insmed Incorporated or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1) to this Form 4.
These options become exercisable with respect to 25% of the shares of common stock subject to this grant on September 10, 2013, the first anniversary of the date of grant, and with respect to an additional 12.5% of the shares of common stock subject to this grant on each sixth month anniversary of September 10, 2013 thereafter through September 10, 2016.
These options become exercisable with respect to 25% of the shares of common stock subject to this grant on September 28, 2013, the first anniversary of the date of grant, and with respect to an additional 12.5% of the shares of common stock subject to this grant on each sixth month anniversary of September 28, 2013 thereafter through September 28, 2016.
These options become exercisable with respect to 25% of the shares of common stock subject to this grant on May 23, 2014, the first anniversary of the date of grant, and with respect to an additional 12.5% of the shares of common stock subject to this grant on each sixth month anniversary of May 23, 2014 thereafter through May 23, 2017.
These options become exercisable upon the achievement of certain performance criteria.
These options become exercisable with respect to 25% of the shares of common stock subject to this grant on October 31, 2014, the first anniversary of the date of grant, and with respect to an additional 12.5% of the shares of common stock subject to this grant on each sixth month anniversary of October 31, 2014 thereafter through October 31, 2017.